Clinical Trial Update: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CYB004, a N,N-dimethyltryptamine analog, in Generalized Anxiety Disorder; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• CYB004

Snippet

Sponsor: Cybin IRL Limited | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: ACTIVE_NOT_RECRUITING